TY - JOUR
T1 - A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
AU - Hansson, Markus
AU - Gimsing, Peter
AU - Badros, Ashraf
AU - Niskanen, Titti Martinsson
AU - Nahi, Hareth
AU - Offner, Fritz
AU - Salomo, Morten
AU - Sonesson, Elisabeth
AU - Mau-Sørensen, Morten
AU - Stenberg, Yvonne
AU - Sundberg, Annika
AU - Teige, Ingrid
AU - Van Droogenbroeck, Jan
AU - Wichert, Stina
AU - Zangari, Maurizio
AU - Frendeus, Björn
AU - Korsgren, Magnus
AU - Poelman, Martine
AU - Tricot, Guido
N1 - ©2015 American Association for Cancer Research.
PY - 2015/6/15
Y1 - 2015/6/15
N2 - PURPOSE: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients.EXPERIMENTAL DESIGN: BI-505 was given intravenously, every 2 weeks, at escalating doses from 0.0004 to 20 mg/kg, with extension of therapy until disease progression for responding or stable patients receiving 0.09 mg/kg or higher doses.RESULTS: A total of 35 patients were enrolled. The most common adverse events were fatigue, pyrexia, headache, and nausea. Adverse events were generally mild to moderate, and those attributed to study medication were mostly limited to the first dose and manageable with premedication and slower infusion. No maximum tolerated dose was identified. BI-505's half-life increased with dose while clearance decreased, suggesting target-mediated clearance. The ICAM-1 epitopes on patient bone marrow myeloma were completely saturated at 10 mg/kg doses. Using the International Myeloma Working Group criteria, 7 patients on extended therapy had stable disease for more than 2 months.CONCLUSIONS: BI-505 can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients. This study was registered at www.clinicaltrials.gov (NCT01025206).
AB - PURPOSE: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients.EXPERIMENTAL DESIGN: BI-505 was given intravenously, every 2 weeks, at escalating doses from 0.0004 to 20 mg/kg, with extension of therapy until disease progression for responding or stable patients receiving 0.09 mg/kg or higher doses.RESULTS: A total of 35 patients were enrolled. The most common adverse events were fatigue, pyrexia, headache, and nausea. Adverse events were generally mild to moderate, and those attributed to study medication were mostly limited to the first dose and manageable with premedication and slower infusion. No maximum tolerated dose was identified. BI-505's half-life increased with dose while clearance decreased, suggesting target-mediated clearance. The ICAM-1 epitopes on patient bone marrow myeloma were completely saturated at 10 mg/kg doses. Using the International Myeloma Working Group criteria, 7 patients on extended therapy had stable disease for more than 2 months.CONCLUSIONS: BI-505 can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients. This study was registered at www.clinicaltrials.gov (NCT01025206).
U2 - 10.1158/1078-0432.CCR-14-3090
DO - 10.1158/1078-0432.CCR-14-3090
M3 - Journal article
C2 - 25712687
SN - 1078-0432
VL - 21
SP - 2730
EP - 2736
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -